A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Ibandronate

Bisphosphonate class · 9 generic manufacturers · 10 ANDAs filed at FDA.

First FDA approval2012-03-19
Generic availableYes · 9 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$39.1M in CY2024 Part D spend1.3M claims · 489K beneficiaries · 329 plans surveyed

Lowest NADAC
$2.79/unit
11 NDCs benchmarked, lowest of all strengths.
Average NADAC
$16.82
Across all dosage forms in distribution.
Highest NADAC
$54.21
Wide spread — brand-strength NDCs still in market.
Plans with PA
55 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Ibandronate used for?

Ibandronate is a Bisphosphonate medication tracked in Medicare Part D.

Is there a generic for Ibandronate?

Yes. 10 ANDAs filed at FDA, 9 generic manufacturers currently shipping.

How much does my plan pay for Ibandronate?

Across 329 Part D plans, Ibandronate averages $16.82/unit (NADAC). Lowest available: $2.79/unit. Highest in distribution: $54.21/unit.

Is Ibandronate on the FDA shortage list?

No. Ibandronate is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Bisphosphonate2 alternatives in D1
01
Alendronate
Brand: Alendronate
$0.121Lowest NADAC
8Generic mfrs
$119.3MCY24 Part D spend
Compare →
02
Zoledronic Acid
Brand: Reclast
$0.465Lowest NADAC
15Generic mfrs
$612,954CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (11 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.